DK

David Kolesky

Principal at MPM BioImpact

Boston, Massachusetts

Invests in

Stages:

  • Min Investment:

    $1,000,000.00
  • Max Investment:

    $150,000,000.00
  • Target Investment:

    $25,000,000.00

Work Experience

  • Principal

    2023

2018 - 2023

  • Principal

    2021 - 2023

  • Senior Associate

    2020 - 2021

  • Associate

    2018 - 2020

  • Fellow

    2018 - 2018

2020 - 2023

  • Co-Founder and Chief Innovation Officer

    2020 - 2023

    Montai Health is unlocking the power of nature with digital technologies to create Anthromolecule medicines to treat and preempt chronic disease. Our ambition is to develop safer, accessible, pathway modulating solutions with the potential to slow and potentially halt disease progression.

  • Acting Chief Scientific Officer

    2020 - 2022

2017 - 2023

  • Co-Founder

    2017 - 2023

    Senda Biosciences is developing new categories of life-changing medicines. With unique insights into the trillions of interspecies molecular connections in the human body, we can create novel treatments for human disease — with applications across a wide variety of therapeutic areas.

2020 - 2021

  • Head of iLabs

    2020 - 2021

    Invaio Sciences is a multi-platform technology company that unlocks the potential of our planet’s interdependent natural systems to solve pressing agriculture, nutrition & environmental challenges.

  • Technology Development Fellow

    2017 - 2018

    Developing technologies related to organ and tissue engineering for clinical translation.

  • Postdoctoral Fellow - Jennifer Lewis Lab

    2016 - 2016

    Developing materials and 3D printing methods for building for building vascularized tissues for in vitro models and, ultimately, tissue replacement. Utilizing principles of microfluidics and bioengineering toward applications in kidney, bone, and blood vessel models.

  • Ph.D. Materials Science and Engineering - Jennifer Lewis Lab

    2012 - 2016

    3D Bioprinting of vascularized tissue constructs: I developed a 3D printing approach to create vasculature within cell-laden tissue structures that could be used for drug screening or tissue engineering. Through collaborations with pharmaceutical companies, we are exploring these avenues.

2014 - 2014

  • Student

    2014 - 2014

    Selected to participate in Harvard Graduate Business Club's Mini-MBA program ('14). Summer program aimed at exposing non-business students to business school concepts and taught using Harvard's Case Method.

  • PHD Student

    2010 - 2012

    Developed conductive inks for printed and wearable electronics. Co-invented high-throughput microfluidic printheads for 3D printing increasing total print speed 64x.

  • Racheff Teaching Fellow

    2012 - 2012

    Teaching Assistant for MSE 405 - Microstructure Determination. Ran and organized X-Ray Diffraction and Raman Spectroscopy labs graded lab reports, exams, and homework.